Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | PRCP | P42785 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10618939 | 0.83 | SLC6A4 (0.50) | SLC6A4SLC6A2OPRM1SLC6A3 | |
| SCHEMBL4540372 | 0.82 | OPRL1 (0.39) | SLC6A4OPRM1DPP4MEN1KMT2A | |
| SCHEMBL4685647 | 0.82 | OPRM1 (0.33) | SLC6A4SLC6A2OPRM1PRCPSIGMAR1 | |
| SCHEMBL5538611 | 0.75 | AKR1C1 (0.38) | OPRM1PRCPSIGMAR1DPP4AKR1C1 | |
| Hydrochloric Acid SCHEMBL6926723 | 0.74 | ALDH1A1 (0.39) | SLC6A2OPRM1PRCPSIGMAR1AKR1C1 | |
| SCHEMBL4991848 | 0.71 | TRPA1 (0.36) | SLC6A4SLC6A2OPRM1DPP4AKR1C1 | |
| SCHEMBL11836311 | 0.69 | CYP3A4 (0.41) | SLC6A4SLC6A2SLC6A3ALDH1A1POLB | |
| SCHEMBL11313363 | 0.66 | SLC6A4 (0.48) | SLC6A4SLC6A2OPRM1SLC6A3ALDH1A1 | |
| SCHEMBL4543656 | 0.66 | TACR1 (0.39) | SLC6A4OPRM1MEN1KMT2A | |
| SCHEMBL9330358 | 0.65 | DPP4 (0.63) | SLC6A4SLC6A2DPP4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080227850-A1 | USE OF NOREPINEPHRINE REUPTAKE MODULATORS FOR PREVENTING AND TREATING VASOMOTOR SYMPTOMS | WYETH (US) | 2008-09-18 | — | — | US | disclosed |
| US-7345096-B2 | Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms | WYETH (US) | 2008-03-18 | — | — | US | disclosed |
| US-20070010543-A1 | Compositions and methods for treating gastrointestinal hypomotility and associated disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010543-A1 | Compositions and methods for treating gastrointestinal hypomotility and associated disorders | HTR3A, HNMT, HTR3B | SLC6A4 71/4885SLC6A2 108/4885OPRM1 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.